atibuclimab (IC14) / Implicit Biosci 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
atibuclimab (IC14) / Implicit Biosci
NCT06513949: Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

Not yet recruiting
2
56
US
Atibuclimab, IC14, Placebo
Implicit Bioscience, University of Washington
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
02/25
08/26
NCT06275893: IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

Recruiting
1/2
5
US
IC14, (atibuclimab)
Implicit Bioscience
Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy 1, Arrhythmogenic Cardiomyopathy
02/25
08/25
NCT06556810: IC14 for Treatment of Acute Decompensated Heart Failure

Not yet recruiting
1/2
10
US
Atibuclimab (IC14), anti-CD14 monoclonal antibody
Implicit Bioscience, University of Virginia, Virginia Commonwealth University
Acute Decompensated Heart Failure
09/25
01/26
NCT04309604: IC14 for ALS Patients Expanded Access

No Longer Available
N/A
US
IC14
Implicit Bioscience, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
 
 
NCT04346277: Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)

No Longer Available
N/A
Europe
IC14, a monoclonal antibody against CD14, anti-CD14
Implicit Bioscience
COVID, ARDS, Human, Ards, SARS-CoV2
 
 

Download Options